BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11056767)

  • 21. Orlistat: a review of its use in the management of obesity.
    Henness S; Perry CM
    Drugs; 2006; 66(12):1625-56. PubMed ID: 16956313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Orlistat. A treatment of limited value for obese persons].
    Taeron C
    Rev Infirm; 2002 Apr; (80):63-4. PubMed ID: 12046132
    [No Abstract]   [Full Text] [Related]  

  • 23. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
    Hill JO; Hauptman J; Anderson JW; Fujioka K; O'Neil PM; Smith DK; Zavoral JH; Aronne LJ
    Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men.
    Pace DG; Blotner S; Guerciolini R
    J Nutr; 2001 Jun; 131(6):1694-9. PubMed ID: 11385055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity drug endorsed by NICE.
    Wise J
    BMJ; 2001 Mar; 322(7287):637. PubMed ID: 11250844
    [No Abstract]   [Full Text] [Related]  

  • 27. Orlistat in the treatment of obesity.
    Ballinger A
    Expert Opin Pharmacother; 2000 May; 1(4):841-7. PubMed ID: 11249520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug treatment of obesity.
    Bray GA
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Apr; 13(1):131-48. PubMed ID: 10932681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orlistat.
    Wong NN; Cheng-Lai A
    Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Changes in lipid profile and paraoxonase activity in obese patients as a result of orlistat treatment].
    Audikovszky M; Pados G; Seres I; Harangi M; Fülöp P; Katona E; Winkler G; Paragh G
    Orv Hetil; 2001 Dec; 142(50):2779-83. PubMed ID: 11820148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?
    Aydin N; Topsever P; Kaya A; Karasakal M; Duman C; Dağar A
    Tohoku J Exp Med; 2004 Mar; 202(3):173-80. PubMed ID: 15065643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit-risk assessment of orlistat in the treatment of obesity.
    Sumithran P; Proietto J
    Drug Saf; 2014 Aug; 37(8):597-608. PubMed ID: 25064699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacotherapy in the treatment of obesity].
    Hamann A
    MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of orlistat to conventional treatment in adolescents with severe obesity.
    Ozkan B; Bereket A; Turan S; Keskin S
    Eur J Pediatr; 2004 Dec; 163(12):738-41. PubMed ID: 15378354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
    Chaput JP; St-Pierre S; Tremblay A
    Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of intense multidisciplinary follow-up and orlistat on weight reduction in a primary care setting.
    Feigenbaum A; Pasternak S; Zusk E; Sarid M; Vinker S
    BMC Fam Pract; 2005 Jan; 6(1):5. PubMed ID: 15679893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Does orlistat really offer help for the treatment of obesity?].
    Orozco P
    Aten Primaria; 1999 Nov; 24(8):445-6. PubMed ID: 10630025
    [No Abstract]   [Full Text] [Related]  

  • 40. Orlistat--a novel weight loss therapy.
    Lucas KH; Kaplan-Machlis B
    Ann Pharmacother; 2001 Mar; 35(3):314-28. PubMed ID: 11261530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.